Bladder / Urothelial Cancer

Bladder and urothelial cancer management now includes enfortumab vedotin plus pembrolizumab as a first-line and perioperative standard, replacing platinum-based regimens in many settings. FGFR3 inhibitors address a genomically defined subset.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Bladder / Urothelial Cancer

• Enfortumab vedotin (Padcev) — Antibody-Drug Conjugate
• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Nivolumab (Opdivo) — Checkpoint Inhibitor
• Atezolizumab (Tecentriq) — Checkpoint Inhibitor
• Erdafitinib (Balversa) — Tyrosine Kinase Inhibitor
• Sacituzumab govitecan (Trodelvy) — Antibody-Drug Conjugate
• Cisplatin (Platinol) — Alkylating Agent
• Gemcitabine (Gemzar) — Antimetabolite